Dynamic Changes of Growth and Thyroid Function in Young Children With Chronic Hepatitis B Treated With Peginterferon Monotherapy

Overview

Journal Pediatr Infect Dis J

Specialty Pediatrics

Date 2024 Sep 30

PMID 39348504

Authors

Qiufeng He

Chuangjie Mao

Zhili Chen

Fangfang Duan

Liang Huang

Rong Hu

Yang Deng

Jun Cheng

Song Yang

Yilan Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Peginterferon (PegIFN) has shown promising results in the treatment of chronic hepatitis B (CHB). This study aimed to evaluate the effects of PegIFN α-2b on growth and thyroid function in young children with CHB.

Methods: A retrospective study was performed by extracting clinical data from children with CHB who received PegIFN α-2b monotherapy at the Public Health Clinical Center of Chengdu between June 2017 and December 2020. Mean, SD, independent samples t test and 1-way repeated analysis of variance were used to evaluate relevant data.

Results: A total of 62 children were included in this study. Overall, significant differences were observed in the weight-for-age z score (WAZ), height-for-age z score (HAZ) and body mass index-for-age z score (BAZ) at different time points ( P < 0.001). WAZ, HAZ and BAZ were not affected by PegIFN α-2b at 24 weeks of treatment (all P > 0.05). WAZ, HAZ and BAZ at the end of treatment and 48 weeks after treatment; WAZ at 96 weeks after treatment were lower than baseline levels (all P < 0.05). No statistical differences were found in HAZ and BAZ at 96 weeks after treatment compared with baseline. Thyroid dysfunction developed in 17.7% of children during the treatment. Thyroid dysfunction was transient and had no effect on growth.

Conclusions: PegIFN α-2b has inhibitory effects on growth and can increase the incidence of thyroid dysfunction in young children with CHB. These effects are generally reversible with the cessation of therapy, although WAZ had not returned to baseline after 96 weeks of observation.

References

Foster G . Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004; 20(8):825-30. DOI: 10.1111/j.1365-2036.2004.02170.x. View

Tsunoda T, Inui A, Kawamoto M, Sogo T, Komatsu H, Fujisawa T . Effects of pegylated interferon-α-2a monotherapy on growth in Japanese children with chronic hepatitis C. Hepatol Res. 2013; 44(3):251-8. DOI: 10.1111/hepr.12118. View

Kozielewicz D, Wietlicka-Piszcz M, Halota W . Long-term outcomes of thyroid dysfunction in patients with chronić hepatitis C treated with pegylated interferon alpha and ribavirin. Przegl Epidemiol. 2018; 71(4):555-569. View

Bortolotti F, Jara P, Barbera C, Gregorio G, Vegnente A, Zancan L . Long term effect of alpha interferon in children with chronic hepatitis B. Gut. 2000; 46(5):715-8. PMC: 1727912. DOI: 10.1136/gut.46.5.715. View

Hamza I, Eid Y, El-Sayed M, Marzaban R, Abdul-Kareem S . Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with the Combined Pegylated Interferon-Ribavirin Therapy. J Interferon Cytokine Res. 2016; 36(9):527-33. DOI: 10.1089/jir.2016.0007. View

Batsis I, Wasuwanich P, Karnsakul W . The management of hepatitis B and hepatitis C in children. Minerva Pediatr. 2018; 71(1):59-75. DOI: 10.23736/S0026-4946.18.05410-5. View

Rashed Y, Khalaf F, Kotb S . Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C. Clin Exp Pediatr. 2020; 63(2):52-55. PMC: 7029667. DOI: 10.3345/kjp.2018.07150. View

Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersoz G . Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother. 2007; 51(8):3020-2. PMC: 1932537. DOI: 10.1128/AAC.00088-07. View

Lai M, Chang M . Updates in the management of hepatitis B in children. Expert Rev Gastroenterol Hepatol. 2019; 13(11):1065-1076. DOI: 10.1080/17474124.2019.1686975. View

10.

Crosse K, Monson E, Beard M, Helbig K . Interferon-Stimulated Genes as Enhancers of Antiviral Innate Immune Signaling. J Innate Immun. 2017; 10(2):85-93. PMC: 5969054. DOI: 10.1159/000484258. View

11.

Jonas M, Balistreri W, Gonzalez-Peralta R, Haber B, Lobritto S, Mohan P . Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology. 2012; 56(2):523-31. PMC: 3382022. DOI: 10.1002/hep.25690. View

12.

Natale V, Rajagopalan A . Worldwide variation in human growth and the World Health Organization growth standards: a systematic review. BMJ Open. 2014; 4(1):e003735. PMC: 3902406. DOI: 10.1136/bmjopen-2013-003735. View

13.

Oppenheim Y, Ban Y, Tomer Y . Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmun Rev. 2004; 3(5):388-93. DOI: 10.1016/j.autrev.2004.03.003. View

14.

Yu M, Chang H, Liaw Y, Lin S, Lee S, Liu C . Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000; 92(14):1159-64. DOI: 10.1093/jnci/92.14.1159. View

15.

Tarim O . Thyroid hormones and growth in health and disease. J Clin Res Pediatr Endocrinol. 2011; 3(2):51-5. PMC: 3119440. DOI: 10.4274/jcrpe.v3i2.11. View

16.

Plockinger U, Kruger D, Bergk A, Weich V, Wiedenmann B, Berg T . Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Am J Gastroenterol. 2007; 102(12):2724-31. DOI: 10.1111/j.1572-0241.2007.01445.x. View

17.

Van Der Spek A, Fliers E, Boelen A . The classic pathways of thyroid hormone metabolism. Mol Cell Endocrinol. 2017; 458:29-38. DOI: 10.1016/j.mce.2017.01.025. View

18.

Rosenthal P, Ling S, Belle S, Murray K, Rodriguez-Baez N, Schwarzenberg S . Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection. Hepatology. 2018; 69(6):2326-2337. PMC: 6465180. DOI: 10.1002/hep.30312. View

19.

You H, Wang F, Li T, Xu X, Sun Y, Nan Y . Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). J Clin Transl Hepatol. 2023; 11(6):1425-1442. PMC: 10500285. DOI: 10.14218/JCTH.2023.00320. View

20.

Serranti D, Indolfi G, Nebbia G, Cananzi M, DAntiga L, Ricci S . Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin. Pediatr Infect Dis J. 2017; 37(4):287-291. DOI: 10.1097/INF.0000000000001791. View